Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/J&J Plan Rivaroxaban Filing For Chronic Indications In 2010

This article was originally published in The Pink Sheet Daily

Executive Summary

An earlier filing for the oral factor Xa inhibitor is planned in the U.S. in 2008 for the prevention of venous thromboembolism.

You may also be interested in...



GSK’S Arixtra “Approvable” For Acute Coronary Syndromes

Firm is seeking FDA approval of fondaparinux for treatment of unstable angina or non-ST segment elevation myocardial infarction and ST-segment elevation MI.

GSK’S Arixtra “Approvable” For Acute Coronary Syndromes

Firm is seeking FDA approval of fondaparinux for treatment of unstable angina or non-ST segment elevation myocardial infarction and ST-segment elevation MI.

Bayer Moves Anti-Thrombotic Into Phase III For Two Indications

Bayer is set to begin Phase III trials for its antithrombotic agent BAY 59-7939 for a general venous thromboembolism indication following promising Phase II results, the company announced June 12

Topics

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel